Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 86.46B | 79.67B | 72.25B | 65.18B | 59.42B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.46B | 79.67B | 72.25B | 65.18B | 59.42B |
| Cost of Revenue | 14.15B | 13.22B | 12.40B | 11.05B | 10.08B |
| Gross Profit | 72.31B | 66.44B | 59.85B | 54.13B | 49.34B |
| SG&A Expenses | 12.95B | 12.56B | 11.89B | 11.42B | 10.73B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.47B | 40.38B | 38.40B | 35.81B | 33.38B |
| Operating Income | 43.99B | 39.28B | 33.85B | 29.37B | 26.05B |
| Income Before Tax | 34.77B | 33.60B | 31.13B | 25.73B | 22.50B |
| Income Tax Expenses | 7.19B | 6.88B | 5.85B | 5.09B | 4.09B |
| Earnings from Continuing Operations | 27.58K | 26.71K | 25.28K | 20.64K | 18.41K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.58B | 26.71B | 25.28B | 20.64B | 18.41B |
| EBIT | 43.99B | 39.28B | 33.85B | 29.37B | 26.05B |
| EBITDA | 46.16B | 41.38B | 35.89B | 31.37B | 27.94B |
| EPS Basic | 30.84 | 29.84 | 28.19 | 22.99 | 20.48 |
| Normalized Basic EPS | 30.92 | 27.64 | 23.55 | 20.29 | 17.93 |
| EPS Diluted | 30.81 | 29.80 | 28.15 | 22.95 | 20.44 |
| Normalized Diluted EPS | 30.88 | 27.61 | 23.52 | 20.26 | 17.90 |
| Average Basic Shares Outstanding | 3.58B | 3.58B | 3.59B | 3.59B | 3.60B |
| Average Diluted Shares Outstanding | 3.58B | 3.59B | 3.59B | 3.60B | 3.60B |
| Dividend Per Share | 6.69 | 6.46 | 6.23 | 6.00 | 5.80 |
| Payout Ratio | 21.68% | 21.66% | 22.10% | 26.09% | 28.28% |